Tech Company Financing Transactions
CellMax Funding Round
Artiman Ventures and private investors invested in a $14 million Series A funding round for CellMax. The funding round closed on 7/27/2016.
Transaction Overview
Company Name
Announced On
7/27/2016
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series A
Investors
Artiman Ventures (Lead Investor) (Dave Lawrence)
private investors (Stan Shih)
Proceeds Purpose
The new $9M in funding is being used for continued product development, ongoing clinical trials, and commercialization of the full range of blood tests, including genetic cancer risk detection, and early cancer detection for colorectal and other cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1271 Oakmead Pkwy.
Sunnyvale, CA 94085
USA
Sunnyvale, CA 94085
USA
Phone
Website
Email Address
Overview
CellMax Assure helps your patients understand and manage their hereditary risk for cancer. Offering a broad menu of testing options and access to a personalized risk management program, CellMax Assure enables you to support your patients with easy, convenient cancer risk testing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Atul Sharan
Chief Financial Officer
Prabhat Goyal
Chief Medical Officer
Mana Javey
Chief Scientific Officer
Rui Mei
Browse more venture capital transactions:
Prev: 7/26/2016: NextInput venture capital transaction
Next: 7/27/2016: SafeBreach venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs